<SEC-DOCUMENT>0001193125-24-202168.txt : 20240816
<SEC-HEADER>0001193125-24-202168.hdr.sgml : 20240816
<ACCEPTANCE-DATETIME>20240816163909
ACCESSION NUMBER:		0001193125-24-202168
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240816
DATE AS OF CHANGE:		20240816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MiNK Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281522
		FILM NUMBER:		241217227

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		212-994-8250

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgenTus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210112
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d844290d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) <BR>Registration No. 333-281522 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g844290g84a01.jpg" ALT="LOGO" STYLE="width:2.87636in;height:0.9125in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>4,640,000 SHARES OF COMMON STOCK </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the disposition from time to time of up to 4,640,000 shares of our common stock, $0.00001 par value per share, which are held by
the selling stockholder named in this prospectus. We issued the shares to the selling stockholder pursuant to a Stock Purchase Agreement, dated May&nbsp;13, 2024 (the &#147;Stock Purchase Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder may resell or dispose of the shares of our common stock, or interests therein, at fixed prices, at prevailing market prices at the
time of sale or at prices negotiated with purchasers, to or through underwriters, broker-dealers, agents, or through any other means described in the section entitled &#147;Plan of Distribution&#148; beginning on page 11 of this prospectus. The
selling stockholder will bear all commissions and discounts, if any, attributable to the sale or disposition of the shares, or interests therein. We will bear all costs, expenses and fees in connection with the registration of the shares. We will
not receive any of the proceeds from the sale of these shares of our common stock by the selling stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq
Capital Market and trades under the symbol &#147;INKT.&#148; On August&nbsp;15, 2024, the last sale price of our common stock as reported on the Nasdaq Capital Market was $0.8210 per share. You are urged to obtain current market quotations for our
common stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves risks. See &#147;<A HREF="#tx844290_2">Risk Factors</A>&#148; beginning on page 5 of this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission, nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
August&nbsp;16, 2024. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_3">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_4">DESCRIPTION OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_6">SELLING STOCKHOLDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_10">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx844290_11">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus, including all documents incorporated herein by reference, together with additional
information described under &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may obtain the information incorporated by reference without charge by
following the instructions under &#147;Where You Can Find More Information&#148; before you make your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have not authorized
anyone to provide you with information different from that contained or incorporated by reference in this prospectus. The selling stockholder may offer to sell, and seek offers to buy, shares of our common stock only in jurisdictions where offers
and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock. </B></P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of selected information contained elsewhere or incorporated by reference in this prospectus. It does not contain all of the
information that you should consider before investing in our securities. You should read this entire prospectus carefully, especially the section entitled &#147;Risk Factors&#148; and the consolidated financial statements and the notes to the
consolidated financial statements incorporated in this prospectus by reference. As used in this prospectus, &#147;MiNK,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148; refer to Agenus Inc. and its consolidated
subsidiaries. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> invariant natural killer T
(&#147;iNKT&#148;) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (&#147;NK&#148;) cells. iNKT
cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Our proprietary platform is designed to
facilitate scalable and reproducible manufacturing for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> delivery. As such, we believe that our approach represents a highly versatile application for
therapeutic development in cancer and immune diseases. We are leveraging our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business activities include product research and development, manufacturing, regulatory and clinical development, corporate finance, and support of our
collaborations. To be successful, our product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. We are a party to an Amended and Restated Intercompany Services Agreement and an
Intellectual Property Assignment and License Agreement with Agenus Inc. (&#147;Agenus&#148;). Under the Amended and Restated Intercompany Services Agreement, Agenus provides us with certain general and administrative support, including, without
limitation, financial, facilities management, human resources and information technology administrative support, and we and Agenus provide each other with certain research and development services and other support services, including legal and
regulatory support. We are also entitled to use Agenus&#146; business offices and laboratory space and equipment in exchange for us contributing a proportionate payment for the use of such facilities and equipment, and we will be covered by certain
Agenus insurance policies, subject to certain conditions, including us paying the cost of such coverage. Under the Intellectual Property Assignment and License Agreement, Agenus exclusively assigned patent rights and
<FONT STYLE="white-space:nowrap">know-how</FONT> related to our technology to us. We also have a field-limited exclusive license under certain Agenus patents and <FONT STYLE="white-space:nowrap">know-how;</FONT> and we retain the rights to expand a
proprietary pipeline of products and technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our most advanced product candidate, <FONT STYLE="white-space:nowrap">agenT-797,</FONT> is an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> allogeneic, native iNKT cell therapy. iNKTs are a potent class of immune cells and serve as master regulators of immune response, possessing the killing power
of NK cells and the memory of <FONT STYLE="white-space:nowrap">T-cells.</FONT> Our proprietary manufacturing platform enables the infusion of these cells in billion-fold quantities, equipping the immune system to combat cancer and other
life-threatening diseases. We have successfully established and launched <FONT STYLE="white-space:nowrap">in-house</FONT> iNKT cell manufacturing and product release capacity, capable of supplying over 5,000 doses annually through a U.S. Food and
Drug Administration (&#147;FDA&#148;)-cleared scalable, fully closed, and automated process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our clinical development of
<FONT STYLE="white-space:nowrap">agenT-797</FONT> is advancing in multiple therapeutic areas of significant unmet needs. These include a Phase 2 trial in 2L gastric cancer and viral acute respiratory distress syndrome (&#147;ARDS&#148;) in
populations of patients where there are critical gaps in current treatment options. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In solid cancers, we completed a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">agenT-797</FONT>
in solid tumor cancers, both as a monotherapy and in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> checkpoint inhibitors pembrolizumab and nivolumab. The trial demonstrated durable
clinical benefits with a tolerable safety profile across various heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> solid tumors, including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (&#147;NSCLC&#148;), testicular
cancer, and gastric cancer. Notably, the median progression-free survival exceeded six months, with approximately 30% of patients experiencing durable disease stabilization, even in cancers refractory to prior therapies such as pembrolizumab and
nivolumab. Building on these results, a randomized, Phase 2 investigator-sponsored trial led by Dr.&nbsp;Yelena Janjigian at Memorial Sloan Kettering Cancer Center is actively enrolling. This trial aims to evaluate the clinical safety and efficacy
of the combination of <FONT STYLE="white-space:nowrap">agenT-797,</FONT> botensilimab (a novel <FONT STYLE="white-space:nowrap">Fc-enhanced</FONT> <FONT STYLE="white-space:nowrap">CTLA-4</FONT> inhibitor), balstilimab
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(anti-PD-1),</FONT></FONT> ramucirumab, and paclitaxel in patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma. The study, which
is expected to enroll approximately 38 patients with advanced, unresectable, or metastatic forms of these cancers, is a priority program for us. Encouraging activity was observed with <FONT STYLE="white-space:nowrap">agenT-797</FONT> in both
monotherapy and combination settings, with durable responses and disease stabilization, as presented at the American Association for Cancer Research (&#147;AACR&#148;) and more recently at the Society for Immunotherapy of Cancer (&#147;SITC&#148;)
conference in November 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In inflammatory diseases, we have completed a phase 1 study<B> </B>of <FONT STYLE="white-space:nowrap">agenT-797</FONT> in
viral ARDS, leveraging the unique anti-inflammatory properties of iNKT cells. Results from our Phase 1 study were published in Nature Communications&#8195;and presented at the American Thoracic Society International Conference over the past two
years. We reported an encouraging survival benefit of 75%, compared to approximately <FONT STYLE="white-space:nowrap">10-22%</FONT> in an <FONT STYLE="white-space:nowrap">in-hospital</FONT> control group and time-matched data from the Centers for
Disease Control and Prevention. In a cohort of 21 patients on mechanical ventilation, survival rates exceeded 70%, with an 80% survival rate among those on venovenous extracorporeal membrane oxygenation. In addition to a survival benefit, <FONT
STYLE="white-space:nowrap">agenT-797</FONT> improved lung function and significantly reduced inflammation and secondary infections, which are major contributors to comorbidity and mortality in intensive care units. Given the lack of approved
therapies for ARDS, we plan to advance <FONT STYLE="white-space:nowrap">agenT-797</FONT> in viral ARDS through strategic collaborations and <FONT STYLE="white-space:nowrap">non-dilutive</FONT> external financing into a randomized Phase 2 trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pipeline is advancing next-generation allogeneic, engineered iNKT programs. Our two most advanced engineered programs are
<FONT STYLE="white-space:nowrap">(1)&nbsp;MiNK-215,</FONT> an <FONT STYLE="white-space:nowrap">IL-15</FONT> armored tumor stromal targeting <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">FAP-CAR-iNKT</FONT></FONT> and <FONT
STYLE="white-space:nowrap">(2)&nbsp;MiNK-413,</FONT> an <FONT STYLE="white-space:nowrap">IL-15</FONT> armored <FONT STYLE="white-space:nowrap">CAR-iNKT</FONT> program targeting BCMA program. <FONT STYLE="white-space:nowrap">MiNK-413</FONT> has
demonstrated tumor clearance and improved persistence in preclinical models, as well as manufacturing and logistical improvements over current BCMA cell therapies. <FONT STYLE="white-space:nowrap">MiNK-215</FONT> has demonstrated efficacy in NSCLC
and melanoma preclinical models, promoting curative responses, eliminating tumor burden in the lungs, and enhancing tumor specific CD8+ T cell infiltration through tumor stroma. These data and programs were presented at AACR in 2024, International
Cancer Immunotherapy Conference in 2023, SITC in 2023, and the American Society of Cell and Gene Therapy in 2023. Most recently, preclinical data from <FONT STYLE="white-space:nowrap">MiNK-215</FONT> in microsatellite stability colorectal cancer
liver metastases were presented at AACR 2024. This presentation highlighted <FONT STYLE="white-space:nowrap">MiNK-215&#146;s</FONT> potent anti-tumor activity, immune activation, and tumor stroma remodeling against this <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> solid tumor setting. Investigational new drug (&#147;IND&#148;) enabling activities are underway we expect to submit an IND to the FDA in 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, we announced a collaboration with ImmunoScape, Inc. (&#147;ImmunoScape&#148;) to discover and develop next-generation <FONT
STYLE="white-space:nowrap">T-cell</FONT> receptor therapies against novel targets in solid tumors. We will combine our unique, proprietary library of T cell antigens with ImmunoScape&#146;s platform for rapid discovery of novel T cell receptors.
ImmunoScape&#146;s unique Deep Immunomics platform enables high-throughput and sensitive screening of T cells against relevant tumor targets for the rapid discovery of rare, therapeutically-relevant <FONT STYLE="white-space:nowrap">T-cell</FONT>
receptors (&#147;TCRs&#148;). We have a proprietary library of phospho-peptide neoantigens derived from a wide range of solid tumors and hematologic malignancies. In this collaborative effort, ImmunoScape will leverage its capabilities in multiplex
antigen screening and <FONT STYLE="white-space:nowrap">in-depth</FONT> T cell profiling to identify relevant TCRs targeting the library of </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
phospho-peptide antigens. We will further characterize these tumor-specific TCRs, leveraging its proprietary capabilities to analyze and select TCR candidates for optimal tumor targeting. Any
intellectual property resulting from the arrangement would be jointly owned by the parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated as AgenTus Biosciences Inc. in Delaware in July 2017. We changed our name to AgenTus Therapeutics, Inc. in October 2017 and to MiNK
Therapeutics, Inc. in June 2021. Our principal executive offices are located at 149 Fifth Avenue Suite 500, New York, NY 10010, and our telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-994-8250.</FONT></FONT>
Our website is minktherapeutics.com. Information contained on, or that can be accessed through, our website is not part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common Stock offered by the selling stockholder</B> </P></TD>
<TD>4,640,000 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds</B> </P></TD>
<TD>We will not receive any proceeds from the sale of shares in this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors</B> </P></TD>
<TD>An investment in our common stock involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 5 for a discussion of certain factors that you should consider before making an investment in our stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Capital Market Symbol</B> </P></TD>
<TD>&#147;INKT&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before purchasing our securities, you should carefully consider the risk factors relating to MiNK
that are incorporated by reference in this prospectus from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023, as well as the risks, uncertainties and additional information set forth in
our SEC reports on Forms <FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> and in the other documents incorporated by reference in this prospectus. For a
description of these reports and documents, and information about where you can find them, see &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Documents By Reference.&#148; Additional risks not presently known or
that we presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations, business and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_3"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference herein, and any prospectus supplement and the documents incorporated therein, contains
forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy and plans and our objectives
for future operations, are forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148;
and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our
financial condition, results of operations, business strategy, short- and long-term business operations and objectives and financial needs. Examples of forward-looking statements include, among others, statements we make regarding: our business
strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, our prospects for initiating partnerships or collaborations, the timing of the introduction of products, the effect of new
accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place significant reliance on our
forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Important factors that could cause actual results and events to differ
materially from those indicated in the forward-looking statements include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, process and results of our research and development programs, preclinical studies and
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate, and the timing of, preclinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> <I>in vivo</I> for multiple programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance any product candidates that we may develop and successfully complete clinical trials and
obtain licensure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to quickly leverage our initial programs and to progress additional programs to create a clinical
portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our strategic plans for our business, programs, product candidates and technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our collaborative relationship with Agenus Inc., as well as our ability to identify and
enter into future license agreements and collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, capital requirements and needs for additional financing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this prospectus are made only as of the date hereof. You should not rely upon forward-looking statements as
predictions of future events. We cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by applicable law, we
undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_4"></A>DESCRIPTION OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of our common stock and certain provisions of our amended and restated certificate of incorporation, or the Amended and Restated
Certificate of Incorporation, and amended and restated bylaws, or the Amended and Restated Bylaws are summaries and are qualified by reference to the Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws, copies of
which are on file with the Commission as exhibits to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023. Please refer to &#147;Where You Can Find More Information&#148; below for
directions on obtaining these documents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.00001 per share. As of June&nbsp;30, 2024, we had 39,445,520 shares
of common stock outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders
and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive
proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available for distribution
to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding
shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred
stock that we may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Our Certificate of Incorporation and Our
<FONT STYLE="white-space:nowrap">By-laws</FONT></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Certificate of Incorporation and Amended and Restated <FONT
STYLE="white-space:nowrap">By-Laws</FONT> contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors but which may have the effect of delaying, deferring or
preventing a future takeover or change in control of us unless such takeover or change in control is approved by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions
include: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Classified board. </I>The Amended and Restated Certificate of Incorporation provides that the board of directors is divided into three classes
of directors, with the classes as nearly equal in number as possible. As a result, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of the board of directors is elected each year. The classification of directors will have the effect
of making it more difficult for stockholders to change the composition of the board. The Amended and Restated Certificate of Incorporation also provides that, subject to any rights of holders of preferred stock to elect additional directors under
specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Action by
written consent; special meetings of stockholders.</I> The Amended and Restated Certificate of Incorporation provides that stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in
lieu of a meeting. The Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws also provide that, except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted
by a majority of the board of directors. Except as described above, stockholders are not be permitted to call a special meeting or to require the board of directors to call a special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advance notice procedures. </I>The Amended and Restated Bylaws establish an advance notice procedure for
stockholder proposals to be brought before an annual meeting of the stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting are only able to consider proposals or nominations
specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who
has given the Secretary of the Company timely written notice, in proper form, of the stockholder&#146;s intention to bring that business before the meeting. Although the Amended and Restated Bylaws do not give the board of directors the power to
approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the Amended and Restated Bylaws may have the effect of precluding the conduct of certain business at a
meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Supermajority approval requirements. </I>The Delaware General Corporation Law, or the DGCL, generally provides that the affirmative vote of a majority of
the shares entitled to vote on any matter is required to amend a corporation&#146;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> unless either a corporation&#146;s certificate of incorporation or <FONT
STYLE="white-space:nowrap">by-laws</FONT> requires a greater percentage. The Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that the affirmative vote of holders of at least 75% of the total votes eligible
to be cast in the election of directors is required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to the Amended and Restated Certificate of Incorporation and Amended and
Restated Bylaws could enable a minority of the Company&#146;s stockholders to exercise veto power over any such amendments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized but unissued
shares. </I>The Company&#146;s authorized but unissued shares of common stock and preferred stock will be available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes,
including future public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an
attempt to obtain control of a majority of the common stock by means of a proxy contest, tender offer, merger or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive forum. </I>Our
Amended and Restated Certificate of Incorporation requires, to the fullest extent permitted by law, that derivative actions brought in the name of the Company, actions against directors, officers and employees for breach of a fiduciary duty and
other similar actions may be brought only in specified courts in the State of Delaware. Under our Amended and Restated Certificate of Incorporation, this exclusive forum provision will not apply to claims that are vested in the exclusive
jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction and explicitly does not apply to actions arising under
federal securities laws, including suits brought to enforce any liability or duty created by the Securities Act, Exchange Act, or the rules and regulations thereunder. Furthermore, our Amended and Restated Certificate of Incorporation provides that
unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any compliant asserting a cause of action arising under the Securities Act.
Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, these provisions may have the effect of discouraging lawsuits against our directors
and officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the DGCL </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in
a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A
&#147;business combination&#148; includes, among other things, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#147;interested stockholder&#148; is a person who, together with affiliates
and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#146;s voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following
conditions: before the stockholder became interested, the corporation&#146;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon consummation of
the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of
determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination was approved by
the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by
the interested stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#147;opt out&#148; of these provisions with an express provision in its original certificate of
incorporation or an express provision in its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> resulting from a stockholders&#146; amendment approved by at least a majority of the outstanding voting shares. The Company
has not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of the Company may be discouraged or prevented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and
registrar for our common stock is Equiniti Trust Company, LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering these shares pursuant to registration rights granted to the selling stockholder. We are not selling any securities under this prospectus
and will not receive any proceeds from the sale or other disposition of the shares covered hereby. We have agreed to pay all costs, expenses and fees relating to registering the shares of our common stock referenced in this prospectus. The selling
stockholder will pay any brokerage commissions and/or similar charges incurred in connection with the sale or other disposition by it of the shares covered hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_6"></A>SELLING STOCKHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have prepared this prospectus to allow the selling stockholder or its pledgees, donees, transferees or other successors in interest, to sell or otherwise
dispose of, from time to time, up to 4,640,000 shares of our common stock (the &#147;Shares&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;13, 2024, we entered into the Stock
Purchase Agreement with the selling stockholder, pursuant to which the selling stockholder purchased the Shares for an aggregate purchase price of $5.8&nbsp;million, or $1.25 per share. The selling stockholder owned approximately12% of the
outstanding shares of our common stock after such purchase. In accordance with the terms of the Stock Purchase Agreement, the selling stockholder has agreed (i)&nbsp;not to dispose of any of the Shares prior to November&nbsp;9, 2024 and (ii)&nbsp;to
vote the Shares in accordance with the recommendations of our board of directors in connection with all matters presented to our stockholders through May&nbsp;14, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with certain registration rights we granted to the selling stockholder pursuant to the Stock Purchase Agreement, we filed with the SEC a
registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> of which this prospectus forms a part, with respect to the resale or other disposition of the shares of common stock offered by this prospectus from time to time on the
Nasdaq Capital Market, in privately negotiated transactions or otherwise. We have agreed to prepare and file amendments and supplements to the registration statement to the extent necessary to keep the registration statement effective for the period
of time required under the Stock Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of the Shares in connection with the Stock Purchase Agreement was not registered under
the Securities Act, in reliance upon exemptions from registration provided by Section&nbsp;4(a)(2) of the Securities Act, because the transactions did not involve any public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the selling stockholder and the shares of common stock that the selling stockholder may offer and sell from
time to time under this prospectus. Neither the selling stockholder nor any of its affiliates, officers, directors or principal equity holders have held any position or office or had any other material relationship with us or our affiliates within
the past three years, other than a Manager of the selling stockholder acting as an observer on our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This table is prepared based on
information supplied to us by the selling stockholder, and reflects holdings as of August&nbsp;13, 2024. As used in this prospectus, the term &#147;selling stockholder&#148; includes the selling stockholder set forth below and any donees, pledgees,
transferees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> selling shares received after the date of this prospectus from the selling stockholder as a gift, pledge, or other <FONT
STYLE="white-space:nowrap">non-sale</FONT> related transfer. Beneficial ownership is determined in accordance with Rule <FONT STYLE="white-space:nowrap">13d-3(d)</FONT> promulgated by the SEC under the Exchange Act, and includes shares of common
stock with respect to which the selling stockholder has voting and investment power. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares in the column &#147;Maximum Number of Shares of
Common Stock that may be Offered Pursuant to this Prospectus&#148; represents all of the shares of our common stock that the selling stockholder may offer under this prospectus. The fourth column assumes the sale of all the shares offered by the
selling stockholder pursuant to this prospectus and that the selling stockholder does not acquire any additional shares of common stock before the completion of this offering. However, because the selling stockholder may sell all or some of its
shares under this prospectus from time to time, or in another permitted manner, we cannot assure you as to the actual number of shares that will be sold by the selling stockholder or that will be held by the selling stockholder after completion of
any sales. The selling stockholder may sell some, all or none of their shares in this offering. We do not know how long the selling stockholder will hold the shares before selling them, and we currently have no agreements, arrangements or
understandings with the selling stockholder regarding the sale of any of the shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial&nbsp;Ownership&nbsp;of</B><br><B>Common&nbsp;Stock&nbsp;Prior&nbsp;to<BR>the&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B><br><B>Number of</B><br><B>Shares of</B><br><B>Common</B><br><B>Stock</B><br><B>that
May</B><br><B>Be&nbsp;Offered</B><br><B>Pursuant&nbsp;to</B><br><B>This</B><br><B>Prospectus</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Beneficial&nbsp;Ownership&nbsp;of</B><br><B>Common&nbsp;Stock&nbsp;After</B><br><B>the Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of Selling Stockholder</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>of&nbsp;Class<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent<BR>of&nbsp;Class<BR>(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GKCC, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,640,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes that all the shares of the selling stockholder covered by this prospectus are sold, and that the
selling stockholder does not acquire any additional shares of common stock before the completion of this offering. However, because the selling stockholder can offer all, some, or none of its common stock, no definitive estimate can be given as to
the number of shares that the selling stockholder will ultimately offer or sell under this prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder, including its pledgees, donees, transferees, distributees, beneficiaries or other successors in interest, may from time to time offer
some or all of the shares of common stock covered by this prospectus. We will not receive any of the proceeds from the sale of the shares of common stock covered by this prospectus by the selling stockholder. We will bear all fees and expenses
incident to our obligation to register the shares of our common stock covered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder may sell all or a portion of
the shares of common stock beneficially owned by it and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the shares of common stock are sold through underwriters or broker-dealers, the
selling stockholder will be responsible for underwriting discounts or commissions or agent&#146;s commissions. The shares of common stock may be sold on any national securities exchange or quotation service on which the securities may be listed or
quoted at the time of sale, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or in transactions otherwise than on these exchanges or systems or in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market and in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at privately negotiated
prices. These sales may be effected in transactions, which may involve crosses or block transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder may use any one or more of
the following methods when disposing of shares or interests therein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> distribution;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">short sales effected after the effective date of the registration statement of which this prospectus is a part;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange
or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broker-dealers may agree with the selling stockholder to sell a specified number of such shares at a stipulated
price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by it and, if it
defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act amending the list of the selling stockholder to include the pledgee, transferee, or other successors in interest as selling stockholder under this prospectus. The selling stockholder also may transfer the
shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the sale of shares of our common stock or interests therein, the selling stockholder may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sales of the common stock in the course of hedging the positions it assumes. The selling stockholder may also sell shares of our common stock short and deliver these securities to close out its
short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or the
creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to
this prospectus (as supplemented or amended to reflect such transaction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the selling stockholder may arrange for other
broker-dealers to participate in sales. If the selling stockholder effects certain transactions by selling shares of common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive
commissions in the form of discounts, concessions or commissions from the selling stockholder or commissions from purchasers of the shares of common stock for whom they may act as agent or to whom they may sell as principal. Such commissions will be
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with applicable rules of the Financial Industry
Regulatory Authority (&#147;FINRA&#148;); and in the case of a principal transaction a markup or markdown in compliance with applicable FINRA rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
aggregate proceeds to the selling stockholder from the sale of the common stock offered by it will be the purchase price of the common stock less discounts or commissions, if any. The selling stockholder reserves the right to accept and, together
with its agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act,
provided that it meets the criteria and conforms to the requirements of that rule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder and any underwriters, broker-dealers or agents
that participate in the sale of the common stock or interests therein may be deemed to be &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any
resale of the shares may be underwriting discounts and commissions under the Securities Act. The selling stockholder is subject to the prospectus delivery requirements of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required pursuant to Rule 424(b) under the Securities Act, the shares of our common stock to be sold, the name of the selling stockholder, the
purchase price and public offering price, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a
post-effective amendment to the registration statement that includes this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if
applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption
from registration or qualification requirements is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling stockholder and any other person participating in a sale
of the common stock registered under this prospectus will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act,
which may limit the timing of purchases and sales of any of the shares of common stock by the selling stockholder and any other participating person. All of the foregoing may affect the marketability of the shares of common stock and the ability of
any person or entity to engage in market-making activities with respect to the shares of common stock. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time)
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available to the selling stockholder for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholder may indemnify any broker-dealer that
participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the securities that may be offered hereby will be passed upon for us by Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of MiNK Therapeutics, Inc. as of December&nbsp;31, 2023 and 2022 and for the years then ended, have been incorporated by
reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein and upon the authority of said firm as experts in accounting and auditing. The audit report covering the
December&nbsp;31, 2023 consolidated financial statements contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about the
entity&#146;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_10"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the Commission. The Commission maintains an Internet site at
http://www.sec.gov that contains the reports, statements and other information about issuers, such as us, who file electronically with the Commission. We also maintain a website at www.minktherapeutics.com, at which you may access these materials
free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the Commission. Information contained on or accessible through our website is not a part of this prospectus or any prospectus supplement, and
the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx844290_11"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; in this prospectus the information we file with the SEC. This helps us disclose certain important
information to you by referring you to the documents we file. The information we incorporate by reference is an important part of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually
updated and those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the
statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. We incorporate by reference each of the documents listed below. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024034672/inkt-20231231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2023 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908);</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024059081/inkt-20240331.htm">March
<U></U>&nbsp;31, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024096142/inkt-20240630.htm">June&nbsp;30, 2024</A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908);</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024014944/inkt-20240212.htm">February&nbsp;14,
 2024</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024060805/inkt-20240513.htm">May&nbsp;16, 2024</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024074233/inkt-20240612.htm">June&nbsp;17, 2024</A>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908);</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017024050064/2024_proxy.htm">Schedule
 14A</A> filed with the SEC on April&nbsp;29, 2024 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908);</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521297781/d232393d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908)</FONT> filed with the Commission on October&nbsp;13, 2021, including any amendment or report filed for the purpose of updating such
description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus additional documents that we may file with the SEC under Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the completion or termination of the offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the
registration statement, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously filed document incorporated by reference into this prospectus is deemed to be modified or superseded for
purposes of this prospectus to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus may contain information that updates, modifies or is contrary to information in one or more of the documents incorporated by reference in this
prospectus. You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus
is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
provide each person, including any beneficial owner, to whom this prospectus is delivered a copy of all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus. You may obtain copies of
these filings, at no cost, through the &#147;Investor&nbsp;&amp; Media&#148; section of our website (www.minktherapeutics.com), and you may request copies of these filings, at no cost, by writing or telephoning us at: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MiNK Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 Fifth
Avenue, Suite 500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New York, NY 10010 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Telephone: (212) <FONT STYLE="white-space:nowrap">994-8250</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained on our website is not a part of this prospectus. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:150pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>August&nbsp;16, 2024 </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g844290g84a01.jpg" ALT="LOGO" STYLE="width:2.87636in;height:0.9125in;">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>4,640,000 Shares of Common Stock </B></P>
<P STYLE="font-size:150pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g844290g84a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g844290g84a01.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_[28$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(S.3(V,S4< @4
M0$UI8W)O<V]F="!7;W)D("T@36E.2R M(%-E;&QI;F<@4W1O8VMH;VQD97(@
M4')O<W!E8W1U<R!?4E]'($1R868 .$))300E       03Z3ARP:W1Y]22H##
MY'W!-3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 &32:  !  $ 9-)H  $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              !<   !(@         !
M                          $              2(   !<
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   !<     %)G:'1L
M;VYG   !(@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG    7     !29VAT;&]N9P   2(    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
M    &U4    !    H    #,   '@  !?H   &SD &  !_]C_X@Q824-#7U!2
M3T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A
M8W-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4A0
M("
M     !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T
M   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D
M;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U
M "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $
M/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H
M=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M   2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V
M+3(N,0
M            6%E:(        /-1  $    !%LQ865H@
M     %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I8
M65H@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
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M<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T
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M.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^)
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M_P ]_P &OF9)#MMND=?F^7I_W7]1^J&_2/' XY^:KV_TIG\Q_-N^G_.?V/\
M@O\ 2+Y?22*!OUVZ/TOU3^ET?S?\S?\ SW\WS1_._P E:0^B..W'"^5DD!O+
MS_8OG\F/R/E\\GZAP_\ #?S/\X[^9_\ 1W_#?OI5_P!*O_F?S/H_SG!_G_\
MT2OEY)'MLM/7?;^7$_3V=_/8G]'_ )[_  _T_HN_HG_=C_T6K _GG_0^@WCZ
M?+_I_P#!_P"C_P"NKY9224=AOM]-WZ:'_++OZ)_-=OZ5_:_X!&ROY['_ )CZ
M?^%^G_Z#_P#"+Y?22^S=)W'S;?RX?ZK_ /_9 #A"24T$(0      50    $!
M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M  %&34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (
M   )    L(=I  0    !    O    .@   !E     0   &4    !061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP.#HQ-B P-#HS-SHT. !R
M<C,Y,C8S-0       Z !  ,    !__\  * "  0    !   !(J #  0    !
M    7          & 0,  P    $ !@   1H !0    $   $V 1L !0    $
M  $^ 2@  P    $  @   @$ !     $   %& @( !     $
M $@    !    2     $X0DE- _T       @          /_A 4Y%>&EF  !-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    D
M  "PAVD !     $   "\    Z    &4    !    90    %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#(T.C X.C$V(# T.C,W.C0X ')R,SDR
M-C,U       #H $  P    '__P  H ( !     $   $BH , !     $   !<
M          8! P #     0 &   !&@ %     0   38!&P %     0   3X!
M*  #     0 "   " 0 $     0   48" @ $     0              2
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MUS@ /"/!6/1(B(@(B("(B B+KJ)6PPOD>;-:"22;((KV^9D;A>!TT5/+\?\
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M[40O;&\/8'--VN%P>L+DM*V79IAS#E^E9O--13TL E)E#W%Q;SZC=I6ZHD1
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M:H/%*#V\C?7' _OT/OA74P7Z-A]O>52O(_UQP/[[#[X5U,%^C8?;WE!]J(B
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ML/<]2JHJV"_-<8[8>YZE6XOQ77T_LX?/N,>^7_#Z0(B*YS!$1 1$0$1$!$1
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M-N7D^JO71>\M_6@[<O)]5>NB]Y!46?Y:3TCWK@%REUGDMH-X]ZX7 )T1#?\
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MF9#31%L;;V!>3Q-UJ6?\HTC\*J*VCB#:N-C&L<Z1UAX8OIV$KK.?:ASB##3
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MD4/P2M+W/D+&Q;K!8"W-2<V5KX]]I\&UTPSO79/$,-L>>W-#R,X2MAP*5[R
M ]NI-N:UG8O$8\*Q2X/A55QI_1"\_:;F2.II)<*I"\3.W)!O,&[8'K]BW7)N
M%#"L-+  #*0\V<3R"PB>;)OY-FU)T^AFM^DWGI^&SWD1%L.0US:-&9<E8JQH
M)<8Q:PO]H+5]F&'8=5X=)'/2T\DL3(P\N:";G>X]7!2#BE*VLH)J>079(+$7
MMS43T%<_)V:ZN&8VIJ^I8R,1C?.ZUQ!O?AXZU\G2\6GL[&BFV72Y,&.=K;[Q
M^23#E_"./ZNI?[,+/[/X2#KAU*?^V%]&'U<5; V:*_1.O;>T.ALOFQK':7":
M9\M5TA:T G<;?B;=:M^[MOLYT6SS;DB9W?71X=1T1<:.FAAWK;VXT"]N"^JQ
MN3?3J7DX!C=-C+)'4@D :&D[[;<;VY^9>K>P64;>"O+6];3&3N @G@HIVB-+
M,ZY8<39O3N/_ ,FJ538&RCK:O0/,V'XE'N[M$Q\AN=>(.@Y\%5FC>G1O<*M$
M:B(GQB8_*6^X6YKJ&(M(M;EVKZ;V=:WM6J9 QNGQ+!*9@Z3IQ&7.): /&(7O
M8EB,-! Z:?>+6V\47XE9UO&V[5RX;TRSCF.NZ-]H>FT'+NN\-UU_Q*DO"[?J
MZ"W#=X*&,7Q%^*9\PN1[KL9(X,NVUA<J9\*\'#J>W[H5.&=[VETN)8YQX,5;
M=]OUE]8U%^" !.=D(6RXSHKOF-3ZMW<5%VSL_P"NE2 -?@I[V*4J[6BJ!S,;
MNXJ*]G[Q#GVJC?XPI#P[6*C)/WJNKH>NGS1\$KLU![ES'!8'%9'.RO<H&FBU
M;:;]2Z^VGA1^^U;0--2M8VFV_8VNOUQ^^U89/5GY-G1>\8_G'U>;LJ%J*KUO
MX,7<Y;U?3@M%V56^!U=OW8NYRWM1B]2&?$/>+?[X"UO:#&YV5\3+;V;22WT_
MHE;'=>=F&G-9@>(4PM\= ]FIMQ:0LKQO$PIT]^3+6WQAK6RF1KLMT; 1O"#7
M7^D5NK00-3<J*MG>)#"\<KL+J2[=IV!C0T7 -QS]JE:ZKPVWIMY-KB6.:ZBU
MI\>O^>KC<"Y=P\ZX-E8YQ#'M<1Q -[+R<VXHW#,&JY27"5L1<P@77@[.ZRLQ
M":>KJ'M=#+$',T /'FLYO'-RPHII;6PSFGI$-XX'0+-OP2W)#U+-K.J2HAC<
M&22QM+C8!S@+KY*W!<.K23545/*3:Y>P%:7M,EK</GPNIIWL;&)W/?I<EHL=
M%LF5LQP8U1L>PR%QWO&:!P-E5-ZS/++=^S9,>*NHQSTGR\'E8KD*CFC<<,%-
M0RV\%\<.H-^.AZEI])F'$,H5U=18E45%8P/$<3G/+  V][7OQN%+M54QTM.^
M9]]UHN;*#LZN_:;&9VT7_"RO#ND\'QB+6M?]TJC-$8^M.[I<,R7U.^/4=:>?
ME^/=/2(BW' $1$!$1 1$0$1$!$1 1$0$1$!$1 6"-5E$''=%[KC-&)6;IO;S
M+L1".G9K.(Y,P^O>73S5;2;#P'M'#_I7D3;*\$E-W56(^R1G^1;ZBKG%2>\-
MNFNU&.-JWF&A1;+,$B\6JQ'VR,_R+V<.R;A] ?B9JIVA'A.:?_\ *V1$C%2.
MT%]=J,D;6O,NN*)L3=UI-O.N=EE%8U)Z]6".I-;CJ640$1$!$1 1$0:GG/ )
ML8FIGPQO<(VN!W7M;Q/G7M9=HWT&$4U-(TM=&VQ!(/,]2])%C%8BTV76SVMB
MC%/:!$19*18=>VG%91!H>%Y4J:7,$%:Z*0,9(7$F1I&M^7'FM[ ("RBQI2*1
MM"_/J+9YB;>'1QL1KS6BX5E2HI,S4=>8I!'$' DR-(U#APX\UOB):L6VF?!&
M+/;%%HK_ '1LPVX 1U[:+*+)2Q;1:WF[*\&88 9W3MEB8X1B-S0#?KN#U+94
M6-JQ:-I68LML5HO2=IA$K,KYBPLF'"\/9-"WP6NEE9<CC^\.:R,G8SB[NCQF
MC,$3M"8967TU',\U+**N,%8\70_FV;O$1$^?7?ZO%RS@,.!TKHH'2NWFM!Z1
MP/ 6Y +V;:+**V(B.SFWO:]IM:=YEQ )%G!?)B]!'B6'STDQ>(Y6[KBP@&WF
MNOM13/5%9FLQ,/#RWENEP)TCJ62=Q>T-/2N!Y^8!>XB*(C;I#*^2V2W->=Y$
M(NB*6#%K#1:CFO(]#C[A+/+5ME:P, C>T"U[\VGK6WHL;4BT;2MPYKX+<^.=
MI17!LFH>F'225X8'#42Q\/ZJWG+V6Z3 Z5L-)).]K6EGQK@38F_(!>VBQKBK
M7LOSZ_49XY<EMX:OEK)M#@$['TDM4_=<7?&O:=2+<@%LX%KK*+.M8K&T-?+F
MOFMS7G>1:-MCTR74G_FQ^\MY6C;8_J74^MC]Y5YO9V^39X=[UC^<?5\>7LN4
MN/8#N5<D[!T+&_%. T+?."O@GV4T;9"('USF7XF6/A_56U;._H@>A'[JVI8U
MQ5M6)EL9=?J,&6U:6Z;M/RMD6@P&9LU/+5N>W>TD>TC7L:%N#18(BMK2*](<
M_-GOFMS9)WD1$62I@BY7FXU@M/B],Z&I?*UI8YGQ9 -G"QX@KTT43$3TEE2]
MJ3%JSUA%U7LIH6SN?325[[V'A2Q]7HK[,(V78933-GEFKVR,)L.E81:UOW?.
MI%15>@IOOLWYXKJIKR\[YZ.D92TT,$9<61,#&EQUL!;5?0B*V(VZ0Y\SO.\N
M)!X#@NJJIFU5/)#*7!KVEIW>*[T38B=IWA'6-;,</JJJ2IBEKG2R.&\.D8 !
M:W-JQA.R_#::H;/)+7B1MQ;I6$6MZ*D9%7&&D3OLWOYGJ>7DYNC6L1RC15U=
MAU3))4A]$P1LW7- (\^B]ZFIFT\+8V%Q:T6%UWHLZUBN\PU+YKY(BMIWB&&B
MRSK8HBR5N!:2T@\"+*-LX9'J:C%IL2PJ&6>HDW6%KI6!NZ&V)UL>0YJ3$6%Z
M1?NV=-JLFEOSXT?Y4PW,4&+4\F)T$,,#7'><V1IL-TVX./-2 ;HB4IRQM#'/
MGG/;FM$1\@<-5XN;L.DQ7 :BDB:7/>6V <!P<#Q.G)>TBRF-XF%>.\X[1>.\
M-;R;@LF#P3-E8YI>&>,X'@#U=JV/6ZRBBM8K&T)RY)RWF]N\N(OQ(U6===%E
M%DK:?F_)M/CH$CW5/2AYD 8]H%[><+5H\ S31-Z*DPR)\7&[Y67O_7"EE%5;
M#6W7LW\7$<N.D4G:8CS1=A>0JBLK8JG&HIJ=\;K@12LMKQZU)&'4C*&DBIHB
MXQQBS2XW*^E%E3'6G93J-7EU'KST\@+ O8W"RBS:SJJ8&U$$D4A(:]I:;<=1
M91_C&R_#:J5T[)J\RFPL)& 6_JJ146%L=;]VQI]7FTT[XK;(K@V54<DK?A+Z
MYC1I=LL?#^JM\RU@%-@%*8:1\SVEK6GI7 GP;VX =:]A%%<5*3O$+,^OSZBO
M+DMO B(K&F(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B M&V
MQ_4NI];'[R(J\WL[?)N\.]ZQ_./J^_9W]$#T(_=6U(BG'ZL*]9[:PB(LVL(B
M("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@__
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
